RVMD Revolution Medicines, Inc.
Company Analysis
Latest News
Revolution Medicines Signs Lease for New 672,000 Sq. Ft. California Headquarters
Revolution Medicines, Inc. has entered into a material agreement to lease four buildings totaling approximately 672,000 square feet in Redwood City,...
🔴 Revolution Medicines falls 4.5% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Perceptive Advisors Doubles Stake in Revolution Medicines (RVMD)
In a notable portfolio move, life sciences investor Perceptive Advisors significantly increased its stake in Revolution Medicines (RVMD) by 104%, bringing its...
FDA Approves Revolution Medicines' RASONQUE™ for Metastatic Pancreatic Cancer
Revolution Medicines, Inc. announced it has received U.S. Food and Drug Administration (FDA) approval for its drug, RASONQUE™ (daraxonrasib). The approval is...
Farallon Capital Reveals New $1.32B Stake in Revolution Medicines
In a recent SEC filing, major investment firm Farallon Capital Management disclosed a substantial new position in Revolution Medicines (RVMD). The filing,...
Baker Bros. Advisors boosts stake in Revolution Medicines by nearly 20%
Noted life sciences investor Baker Bros. Advisors significantly increased its position in Revolution Medicines (RVMD), according to a recent SEC filing. The...
Baker Bros. Nearly Doubles Revolution Medicines Stake, Exits Three
In its second-quarter 13F filing, specialist investment firm Baker Bros. Advisors revealed a portfolio valued at $19.96 billion. As a prominent and highly...
Revolution Medicines' second quarter loss widens as it raises FY26 expense guidance to $2.1B-$2.2B
Revolution Medicines reported a wider-than-expected second quarter net loss of $644.4 million, or ($3.06) per share, missing the consensus estimate of a $1.93...
Revolution Medicines Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Revolution Medicines is expected to report a Q2 2026 consensus revenue of $1.8 million and an adjusted EPS loss of $1.93, while the stock currently trades at...
Revolution Medicines Reports 82% Response Rate for Targeted Pancreatic Cancer Therapy
Revolution Medicines presented Phase 1/2 trial data for its cancer therapy, zoldonrasib, at the ESMO Gastrointestinal Cancers Congress. The studies evaluated...
Revolution Medicines Joins Russell 1000 Growth, Needham Hikes Target to $235
Revolution Medicines joined the Russell 1000 Growth Benchmark on June 29, 2026. This inclusion increases the company's visibility among institutional investors...
🟢 RVMD extends move to 5.3% up
RVMD is trading at $191.79, up 5.3% versus the comparison close of $182.08 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 RVMD is trading 4.4% up today as analysts hike price targets and reaffirm Buy ratings
RVMD is trading 4.4% up at $190.08 after several bullish analyst actions raised price targets and reaffirmed Buy ratings. • The stock is extending its recent...